Immunicum AB will move its in-house research and process development activities into a new facility at the Leiden Bio Science Park, the Netherlands.
The company said Wednesday it has signed a long-term lease with developer Kadans Science Partner for approximately 1,100 square meters of laboratory and office space in the Plus Ultra Leiden, a new building currently under development. Furthermore, Immunicum has the option to rent an additional 1,100 square meters to further support its future growth. The new location, that is expected to be fully commissioned in 2022, will serve as Immunicum’s core research and development hub.
Sven Rohmann, the company’s CEO, expects the facility to enable the company to rapidly and cost-effectively continue the development of potential transformative treatment options for cancer patients.
“Following the combination with DCprime, we have strengthened our team of leading experts and we will establish this new facility as a center of excellence, thereby gaining full control over crucial product development aspects of our cell-based therapies,” he said.
Immunicum said in the press release that the new facility will house its entire Leiden-based operation, while multiple laboratory suites will support its R&D activities for the now expanded pipeline of next-generation cell-based immunotherapies following the business combination.